Rabeprazole Sodium Enteric Coated Delayed-Release Tablets

Rabeprazole sodium enteric coated delayed-release tablets are formulated to protect the active ingredient from degradation in gastric acid, ensuring release in the intestine for optimal acid suppression. The formulation provides reliable and sustained control of gastric acid secretion.

• Proton pump inhibitor for effective reduction of stomach acid
• Enteric coating ensures protection from acidic environment
• Delayed-release mechanism for targeted intestinal delivery
• Provides prolonged and consistent acid suppression
• Supports healing of acid-related mucosal damage
• Manufactured under stringent quality and compliance standards

This medication is widely used in the treatment and prevention of acid-related gastrointestinal disorders. It helps reduce symptoms and promotes healing of the digestive tract.

• Gastroesophageal reflux disease (GERD)
• Acid reflux and persistent heartburn
• Gastric and duodenal ulcers
• Zollinger–Ellison syndrome
• Management of erosive esophagitis

The enteric coated delayed-release formulation enhances stability and ensures effective drug delivery at the desired site of action. It improves therapeutic outcomes and patient convenience.

• Protects active ingredient from stomach acid degradation
• Ensures targeted release in the intestine
• Provides long-lasting acid control
• Improves treatment effectiveness and consistency
• Convenient dosing for better patient compliance
• Stable formulation suitable for large-scale production and global supply